The critical path pg. 2
There are other issues. The FDA needs more money to monitor drugs already on the market. Industry must invest more in drug safety. And, says Woosley, university scientists should play a greater role as industry watchdogs and helpful partners.
“We need to be there to keep their feet to the fire, but also to share our expertise and make sure that the drugs are developed in the very best way,” he says.